The Impact of Antiretroviral Drugs on HBV Infection
Oluwaseun O. Falade-Nwulia, MD, MPH
Assistant Professor of Medicine, Division of Infectious Diseases
Johns Hopkins University School of Medicine, Baltimore, MD
Videos of live meetings of PRN in NYC are owned and published by Physicians’ Research Network, Inc.
Copyright © 2016. All rights reserved.
Oluwaseun (Seun) Falade-Nwulia is an Assistant Professor at the Johns Hopkins University School of Medicine and in the recent past was also Medical Director of the Baltimore City Health Department HIV Early Intervention Initiative and Direct Observed Therapy Programs. She also provides clinical care to HIV and hepatitis C infected patients at the Johns Hopkins Hospital. In the last 3 years, Seun has focused her clinical and academic pursuits on educating clinicians and public health practitioners about STDs, HIV, and hepatitis. Her research has focused on understanding the distribution and impact of hepatitis B and C in at risk populations. She is also actively involved in research aimed at improving HIV and hepatitis C testing, access to and retention in care in for both HIV and hepatitis in medically underserved communities.
At the completion of this educational session, learners will:
- Understand the epidemiology of HBV infection.
- Know the impact of HIV infection on HBV-related liver outcomes.
- Be aware of the impact of antiretroviral drugs on HBV.
- Have a better understanding of HBV in MSM with, and at risk for, HIV-infection.
This CME activity was approved for AMA PRA Category 1 Credit™
on February 9, 2016 and will terminate February 8, 2019.
The target audience is all physicians, NPs and PAs involved or interested in HIV education.
This online video and post-activity evaluation are one hour in length.
After you complete the video portion of this educational activity there will be a post-activity evaluation and quiz.
You must achieve at least 70% correct to receive your CME certificate.
If successful, you will be provided instructions to print your CME certificate at the completion of this activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Medical Society of the State of New York (MSSNY) and the Physicians’ Research Network (PRN). MSSNY is accredited by the ACCME to provide continuing medical education for physicians.
The Medical Society of the State of New York designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™
. Physicians should claim only the credit commensurate with extent of their participation in the activity.
Policies and standards of MSSNY require that speakers and planners for CME activities disclose any relevant financial relationships they may have with commercial interests whose products, devices or services may be discussed in the content of a CME activity.
Dr. James Braun (Planner/Course Director) had no relevant financial relationships to disclose.
Dr. Falade-Nwulia (Presenter) had no relevant financial relationships to disclose. Dr. Falade-Nwulia submitted her slides in advance for adequate peer review, and will support her presentation and clinical recommendations with the best available evidence from the medical literature.
This PRN CME activity is funded in part by unrestricted educational grants from:
Bristol-Myers Squibb, Gilead Sciences, Merck & Co, and ViiV Healthcare.
To obtain CME credit for this PRN program, please visit the PRN Video Channel
at the Clinical Education Initiative (CEI) web site. PRN and the Medical Society of the State of New York (MSSNY) jointly sponsor PRN enduring materials for CME, and provide them at no cost to the AIDS Institute of the New York State Department of Health (NYSDOH) for broadcast through the CEI. We thank the NYSDOH for making our CME programs available to a wider audience, and hope you will also browse the many other educational opportunities offered by the CEI.